MRNA:OTCQB-Marina Biotech Inc (USD)

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 110.59

Change

+3.18 (+2.96)%

Market Cap

USD 0.02B

Volume

4.57M

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-0.22 (-0.06%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc

-7.48 (-0.84%)

USD 106.98B
ARGX argenx NV ADR

+4.20 (+1.14%)

USD 22.08B
BNTX BioNTech SE

+0.50 (+0.58%)

USD 21.93B
GMAB Genmab AS

+0.69 (+2.51%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc

-0.40 (-0.28%)

USD 18.18B
RPRX Royalty Pharma Plc

-0.11 (-0.39%)

USD 18.18B
BGNE BeiGene Ltd

+5.02 (+3.38%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc

-1.26 (-1.53%)

USD 16.06B
INCY Incyte Corporation

+0.50 (+0.98%)

USD 12.79B

ETFs Containing MRNA

MRN3:LSE Leverage Shares 3x Long M.. 300.13 % 0.00 %

+0.86 (+0.48%)

USD 0.37M
GERM ETFMG Treatments Testing .. 7.50 % 0.00 %

+0.43 (+0.48%)

USD 0.01B
CURE:XETRA VanEck Genomics and Healt.. 6.82 % 0.00 %

+0.24 (+0.48%)

USD 6.89M
MSGR 6.26 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 5.74 % 0.35 %

+0.82 (+0.48%)

USD 0.45B
XGES:LSE Xtrackers MSCI Genomic He.. 5.20 % 0.00 %

+0.39 (+0.48%)

USD 3.51M
IDNA iShares Genomics Immunolo.. 5.14 % 0.00 %

+0.36 (+0.48%)

USD 0.14B
GNOM Global X Genomics & Biote.. 5.13 % 0.00 %

+0.11 (+0.48%)

USD 0.10B
HVAX:CA 4.95 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.85 % 0.00 %

+0.49 (+0.48%)

USD 3.51M
XDNA:CA iShares Genomics Immunolo.. 4.69 % 0.00 %

+0.54 (+0.48%)

CAD 4.63M
GNOG:LSE Global X Genomics & Biote.. 4.45 % 0.00 %

+0.10 (+0.48%)

USD 8.88M
IBBQ Invesco Nasdaq Biotechnol.. 4.43 % 0.00 %

+0.18 (+0.48%)

USD 0.03B
GN0M:XETRA Global X Genomics & Biote.. 4.40 % 0.00 %

+0.13 (+0.48%)

USD 7.05M
BTEC:SW iShares Nasdaq US Biotech.. 4.20 % 0.00 %

+0.07 (+0.48%)

USD 0.46B
IBB iShares Biotechnology ETF 3.83 % 0.47 %

+0.82 (+0.48%)

USD 7.79B
BIB ProShares Ultra Nasdaq Bi.. 3.35 % 0.95 %

+0.72 (+0.48%)

USD 0.10B
CDNA:CA CI Bio-Revolution ETF 3.19 % 0.00 %

N/A

CAD 4.55M
XNNS:LSE Xtrackers MSCI Innovation.. 2.88 % 0.00 %

+0.83 (+0.48%)

USD 7.55M
XNNV:LSE Xtrackers MSCI Innovation.. 2.88 % 0.00 %

+0.91 (+0.48%)

USD 7.55M
BBP Virtus LifeSci Biotech Pr.. 2.61 % 0.79 %

+0.58 (+0.48%)

USD 0.02B
XNNV:XETRA Xtrackers MSCI Innovation.. 2.59 % 0.00 %

+1.03 (+0.48%)

USD 7.55M
LSEQ Harbor Long-Short Equity .. 2.50 % 0.00 %

+0.12 (+0.48%)

USD 0.01B
HTEC Robo Global® Healthcare .. 2.06 % 0.00 %

+0.14 (+0.48%)

USD 0.06B
DOCG:LSE L&G Healthcare Breakthrou.. 1.90 % 0.00 %

+13.15 (+0.48%)

USD 0.08B
DOCT:LSE L&G Healthcare Breakthrou.. 1.90 % 0.00 %

N/A

USD 0.08B
TAEQ 1.46 % 0.00 %

N/A

N/A
QQEW First Trust NASDAQ-100 Eq.. 1.09 % 0.60 %

+0.60 (+0.48%)

USD 2.19B
CURE:AU ETFS S&P Biotech ETF 1.09 % 0.00 %

-1.58 (0.48%)

USD 0.04B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

+0.03 (+0.48%)

USD 1.19B
FLAG 0.00 % 1.52 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

-0.46 (0.48%)

CAD 0.05B
LS:CA Middlefield Healthcare & .. 0.00 % 2.21 %

N/A

CAD 0.16B
HWF:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+0.48%)

USD 0.49B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+0.48%)

USD 0.49B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.06 (+0.48%)

USD 0.49B
RYH 0.00 % 0.40 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

+0.08 (+0.48%)

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.08 (+0.48%)

USD 0.52B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

+0.15 (+0.48%)

USD 0.07B
MRNS:LSE Leverage Shares -3x Short.. -299.92 % 0.00 %

-0.01 (0.48%)

USD 0.12M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.18% 59% D- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.18% 59% D- 74% C
Trailing 12 Months  
Capital Gain -25.68% 40% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.68% 40% F 28% F
Trailing 5 Years  
Capital Gain 443.44% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 443.44% 95% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 140.75% 93% A 96% N/A
Dividend Return 140.75% 93% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 220.27% 13% F 7% C-
Risk Adjusted Return 63.90% 97% N/A 89% A-
Market Capitalization 0.02B 100% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector